222 related articles for article (PubMed ID: 26905753)
21.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
Li Y; Meng L; Shi T; Ren J; Deng Q
Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
[TBL] [Abstract][Full Text] [Related]
24. Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence.
Eismann L; von Walter P; Jung A; Chaloupka M; Rodler S; Westhofen T; Buchner A; Stief CG; Stadler T; Schlenker B
Urol Oncol; 2023 Jul; 41(7):325.e1-325.e8. PubMed ID: 37179150
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
[TBL] [Abstract][Full Text] [Related]
26. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
27. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
28. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
30. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
31. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.
Møller M; Strand SH; Mundbjerg K; Liang G; Gill I; Haldrup C; Borre M; Høyer S; Ørntoft TF; Sørensen KD
Sci Rep; 2017 Jan; 7():40636. PubMed ID: 28084441
[TBL] [Abstract][Full Text] [Related]
33. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
Wang L; Xie PG; Lin YL; Ma JG; Li WP
Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
[TBL] [Abstract][Full Text] [Related]
34. High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients.
Chen L; Xiong W; Qi L; He W
BMC Urol; 2023 Jul; 23(1):112. PubMed ID: 37403079
[TBL] [Abstract][Full Text] [Related]
35. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
37. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
Strand SH; Hoyer S; Lynnerup AS; Haldrup C; Storebjerg TM; Borre M; Orntoft TF; Sorensen KD
Clin Epigenetics; 2015; 7():111. PubMed ID: 26478752
[TBL] [Abstract][Full Text] [Related]
38. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
39. A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.
Angulo JC; Lopez JI; Dorado JF; Sanchez-Chapado M; Colas B; Ropero S
Urol Int; 2016; 97(1):16-25. PubMed ID: 27220660
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis.
Abildgaard MO; Borre M; Mortensen MM; Ulhøi BP; Tørring N; Wild P; Kristensen H; Mansilla F; Ottosen PD; Dyrskjøt L; Ørntoft TF; Sørensen KD
Int J Cancer; 2012 Feb; 130(4):885-95. PubMed ID: 21445975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
